TNGX SCHEDULE 13G/A: SEC filing

Farallon Capital Management

Filed with the SEC on · accession 0000908834-26-000536

TNGX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Farallon Capital Management filed an amended Schedule 13G reporting beneficial ownership of 8,543,875 shares (4.9%) of Tango Therapeutics, including 4,550,688 common shares and 3,993,187 pre-funded warrants. The stock moved -5.2% by the first close after the filing.

Summary of the filing

Farallon Capital Management filed an amended Schedule 13G reporting beneficial ownership of 8,543,875 shares (4.9%) of Tango Therapeutics, including 4,550,688 common shares and 3,993,187 pre-funded warrants. The filing is a passive investment disclosure with no stated intent to influence company control.

Key details

Aggregate shares beneficially owned$8.5M
Common shares held$4.6M
Pre-funded warrants held$4.0M
Subject companyTango Therapeutics, Inc.
Reporting person / investment managerFarallon Capital Management, L.L.C.
Fund holding sharesFarallon Capital Partners, L.P.
Fund holding sharesFarallon Capital Institutional Partners, L.P.
Fund holding sharesFarallon Capital Institutional Partners II, L.P.
Fund holding sharesFarallon Capital Institutional Partners III, L.P.
Fund holding sharesFarallon Capital Offshore Investors II, L.P.
Fund holding sharesFarallon Capital (AM) Investors, L.P.
Fund holding sharesFarallon Capital F5 Master I, L.P.
Fund holding sharesFarallon Healthcare Partners Master, L.P.
Managing member, farallon capital managementJoshua J. Dapice
Managing member, farallon capital managementPhilip D. Dreyfuss
Managing member, farallon capital managementHannah E. Dunn
Managing member, farallon capital managementVarun N. Gehani
Managing member, farallon capital managementNicolas Giauque
Managing member, farallon capital managementAvner A. Husen
Managing member, farallon capital managementDavid T. Kim
Managing member, farallon capital managementMichael G. Linn
Managing member, farallon capital managementPatrick (Cheng) Luo
Managing member, farallon capital managementThomas G. Roberts, Jr.
Managing member, farallon capital managementEdric C. Saito
Managing member, farallon capital managementDaniel S. Short
Managing member, farallon capital managementAndrew J. M. Spokes
Managing member, farallon capital managementJohn R. Warren
Managing member, farallon capital managementMark C. Wehrly

How TNGX stock reacted

Close before

$25.50

Nov 13, 2026

First close after

-5.22%

$24.17

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for TNGX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TNGX?

Click here

Frequently asked questions

What did TNGX file with the SEC on Nov 16, 2026?

TNGX filed a SCHEDULE 13G/A (SEC filing). Farallon Capital Management filed an amended Schedule 13G reporting beneficial ownership of 8,543,875 shares (4.9%) of Tango Therapeutics, including 4,550,688 common shares and 3,993,187 pre-funded warrants. The filing is a passive investment disclosure with no stated intent to influence company control.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did TNGX stock react to this filing?

TNGX closed at $25.50 before the filing and $24.17 on Nov 16, 2026 (-5.22%).

Other TNGX SEC filings

Get alerts when TNGX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days